Maze Therapeutics Inc.
XNAS:MAZE 12:24:25 AM EDT
| Market Cap (Intraday) | 1.45B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $26.29 |
| 50-Day MA | $33.41 |
| 200-Day MA | $32.39 |
Maze Therapeutics Inc. Stock, XNAS:MAZE
171 Oyster Point Boulevard, Suite 300, San Francisco, California 94080
Phone: +1.650.850.5070
Number of Employees:
Description
Maze Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM diseases. Its pipeline includes Compass platform, which allows to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process to refer a variant functionalization. The company was founded by Mark Daly, Aaron D. Gitler, Stephen Elledge, Sekar Kathiresan, and Jonathan S. Weissman on August 28, 2019 and is headquartered in San Francisco, CA.